Skip to main content

Table 4 Comparison of adjusted demographic and baseline clinical characteristics of patients from the international observational studies (RIVER and XANTUS), studies from Japan (EXPAND and XAPASS)

From: International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER)

 

RIVER

XANTUS

EXPAND

XAPASS

Patients, n

5072

6784

7141

11,308

Patient characteristics

 Sex, male (%)

55.7

59.2

67.7

61.9

 Age, mean (SD)

69.5 (11.0)

71.5 (10.0)

71.6 (9.4)

73.1 (9.9)

 BMI (Kg/m2), mean (SD)

29.2 (5.7)

28.3 (5.0)

NA

23.7 (3.8)

 Creatinine clearance (mL/min), mean (SD)

83.7 (35.6)

NA

69.7 (26.2)

67.7 (28.9)

 < 15 mL/min (%)

0.02

0.3

NA

0.03

 ≥ 15 to < 30 mL/min (%)

0.7

1.1

1.9

2.8

 ≥ 30 to < 50 mL/min (%)

7.9

8.0

18.9

21.1

 ≥ 50 mL/min (%)

53.4

56.2

74.6

68.0

 Missing (%)

38.0

34.4

4.7

8.2

Rivaroxaban dose/dosing frequency

 10 mg once daily

105 (2.1)

NA

NA

NA

 15 mg once daily

1008 (20.0)

1410 (20.8)

NA

NA

 20 mg once daily

3867 (76.5)

5336 (78.7)

NA

NA

 10 mg twice daily

10 (0.2)

NA

NA

NA

 15 mg twice daily

29 (0.6)

NA

NA

NA

 20 mg twice daily

22 (0.4)

NA

NA

NA

 10/15/20 mg other dosing Regimen

12 (0.2)

35 (0.5)

NA

NA

 CHADS2 score, mean (SD)

1.9 (1.2)

2.0 (1.3)

2.1 (1.3)

2.2 (1.3)

 CHA2DS2-VASc score, mean (SD)

3.2 (1.6)

3.4 (1.7)

3.4 (1.7)

NA

Comorbidity/medical history

 Congestive heart failure (%)

21.5

18.6

26.1

25.0

 Hypertension (%)

77.0

74.7

70.9

74.3

 Diabetes mellitus (%)

24.3

19.6

24.3

22.3

 History of stroke/systemic embolism/TIA (%)

13.4

19.0

24.1

23.7

Type of AF

 Paroxysmal (%)

34.2

40.7

44.8

NA

 Non-paroxysmal (persistent/permanent) (%)

31.6

40.8

55.2

NA

 First diagnosed (%)

34.2

18.5

NA

NA